Notably, targeting CD36 with function-blocking antibodies or genetic ablation reduced the tumor burden and metastasis in OSCC, gastric, and ovarian cancer xenograft mouse models, with reductions of up to 90% observed in the size of lymph node metastases [14,23,54]. This evidence concerns the gene CD36 and ovarian carcinoma.